Background: Perioperative anaphylaxis is a life-threatening clinical condition characterized by severe respiratory and cardiovascular manifestations. Neuromuscular blocking agents are the most common cause of anaphylaxis during anesthesia.
Case: We report a case of rocuronium-induced anaphylaxis treated with sugammadex. A 75-year-old female was scheduled to undergo spinal surgery. She had no history of allergies. After the injection of rocuronium, she developed hypotension and tachycardia, and skin rashes and urticaria appeared. The patient received sugammadex to delay the operation, and her vital signs were stabilized. On the 76th postoperative day, we performed intradermal tests for rocuronium, propofol, and cefazolin. Diluted rocuronium alone induced 14 mm of flare and 8 mm of wheal within 5 min, both of which disappeared within 15 min after the intradermal injection.
Conclusions: Sugammadex is a useful rocuronium antagonist that can be used to treat rocuronium-induced anaphylaxis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861895 | PMC |
| http://dx.doi.org/10.17085/apm.20074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models.
Sci Transl Med
September 2024
Institut Pasteur, Université Paris Cité, INSERM UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.
Article Synopsis
- * Sugammadex can reverse the effects of rocuronium-induced neuromuscular blockade but may also provoke anaphylaxis, indicating a need for better treatment options.
- * Research into the antibodies of patients with rocuronium sensitivity found a diverse range that can activate anaphylaxis; high-affinity antibodies capable of reversing rocuronium effects were isolated, suggesting new avenues for diagnosis and treatment.
Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. Comment on Br J Anaesth 2024; 132: 45-52.
Br J Anaesth
April 2024
Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan. Electronic address:
Rocuronium, a nondepolarizing neuromuscular blocking agent used for muscle relaxation especially during endotracheal intubation, can cause hypersensitivity reactions. This article provides an overview of anaphylactic reactions; risk factors; and the pathophysiology, presentation, diagnosis, treatment, and nursing implications associated with rocuronium-induced anaphylaxis. Life-threatening anaphylaxis can be immunoglobulin E-mediated or non-immunoglobulin E-mediated and usually occurs after the first dose.
View Article and Find Full Text PDFComparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial.
J Clin Med
November 2022
Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
This current phase II clinical trial was to compare the effect and safety of adamgammadex, a new cyclodextrin-based selective relaxant binding agent, with sugammadex to reverse rocuronium-induced neuromuscular block. Patients were randomised to receive adamgammadex (4 or 6 mg kg) or sugammadex (2 mg kg, as a positive control group) at the reappearance of the second twitch (T) in response to TOF stimulation. The standard safety data were collected.
View Article and Find Full Text PDFSuccessful management of rocuronium-induced anaphylaxis with sugammadex: A case report.
J Int Med Res
July 2022
Department of Anaesthesiology, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan.
Article Synopsis
- Anaphylaxis during anesthesia is rare, but neuromuscular blocking drugs cause 62% of these cases, with rocuronium being a common culprit.
- Sugammadex, a drug that quickly reverses the effects of rocuronium by encapsulating it, was used successfully in a 68-year-old patient who experienced severe anaphylaxis during surgery.
- The case suggests that sugammadex can be a valuable tool in managing rocuronium-induced anaphylaxis, especially when traditional treatments fail.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!